Document Type
Original Article
Abstract
Background: About 1 in 15 women are affected by polycystic ovarian syndrome (PCOS), a complex endocrine condition with a variety of causes. Excessive androgen secretion or activity is the primary endocrine disturbance, and aberrant insulin activity is seen in a large proportion of women. Aim and objectives: To contrast the efficacy of a prolonged letrozole treatment for treating clomiphene-resistant PCOS to that of a short letrozole therapy and a placebo. Subjects and methods: This prospective, interventional, research was done at Qena university hospital, Obstetrics and Gynecology department. All cases were subdivided into three groups: Group (A): 40 patients took short letrozole, Short letrozole group. Group (B): 40 patients took long letrozole, Long letrozole group. Group(C): 40 patients took placebo, Placebo group. The research lasted anywhere from 6-12 months. Result: There is a significant distinction among the groups regarding endometrial thickness with hCG trigger injection. Ovulation incidence was substantially greater in group B contrasted with group A contrasted with group C. Pregnancy incidence was substantially higher in group B contrasted with group A contrasted with group C. Conclusion: More and larger mature follicles, Elevated endometrial thickness & the number of pregnancies can be achieved with prolonged letrozole medication contrasted with shorter letrozole medication.
Keywords
Polycystic Ovary Syndrome (PCOS); Letrozole regimen; clomiphene.
Subject Area
Obstetrics and Gynecology
How to Cite This Article
Wafa, Yehia; El-Omda, Fahd AbdelAl; and Kamaly, Mohammed Atef Mohammed
(2023)
"Extended Letrozole Regimen For Treatment Of Clomiphene Resistant PCO Patient,"
Al-Azhar International Medical Journal: Vol. 4:
Iss.
12, Article 50.
DOI: https://doi.org/10.58675/2682-339X.2162
